KKR (NYSE:KKR) Partners With Boston Scientific And Ajax Health In US$4B Venture To Tackle Heart Failure

Last week, Ajax Health announced the formation of FlowMod, a new venture in collaboration with Boston Scientific Corporation and KKR (NYSE:KKR), aimed at developing a heart failure treatment system. This significant partnership likely influenced KKR's stock, which saw a 1% price increase amidst a general market decline. KKR's involvement in high-growth healthcare through its strategic growth fund highlights its focus on promising health initiatives. While this news brought positive attention, the broader market environment was challenging, with major indices, including the Dow Jones and S&P 500, experiencing a 2.5% drop due to investor concerns surrounding newly imposed tariffs. Despite these market headwinds, KKR's resilience could suggest investor confidence in its strategic healthcare investments, which complemented interest in potential acquisitions, such as its rumored pursuit of a stake in Starbucks' China business. Overall, these developments amid market turbulence illustrate KKR's positioning within an evolving investment landscape and its reputation for leveraging growth opportunities.

Click here to discover the nuances of KKR with our detailed analytical report.

Over the last five years, KKR's total shareholder return has been very large at 487.72%. This impressive growth outpaced the Capital Markets industry and the broader US market over the past year. Several factors contributed to this performance, including key developments in earnings, strategic alliances, and mergers and acquisitions. The positive earnings announcement in August 2021, where Q2 revenue increased to US$3.14 billion from US$1.33 billion, marked a significant turning point. The formation of strategic alliances, such as the partnership with Telefónica Colombia, reinforced KKR's emphasis on expanding digital infrastructure.

Moreover, KKR's involvement in high-profile acquisitions, like expressing interest in purchasing a stake in Starbucks' China business in February 2025, highlighted its aggressive growth strategy. The company's efforts in the healthcare sector, demonstrated by the recent formation of FlowMod, further underlined its commitment to future expansion. Dividend declarations and continuous investment in various sectors maintained shareholder value, while talks of increased acquisitions hinted at a sustained focus on operational enhancement.

• See whether KKR's current market price aligns with its intrinsic value in our detailed report
• Assess the downside scenarios for KKR with our risk evaluation.
• Is KKR part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com